Subscribe to Newsletter


The COVID-19 pandemic has dominated conversations over the past two years, so it’s no surprise that a major player in this area would take the category by storm. The Pfizer-BioNTech vaccine was the first COVID-19 vaccine to be approved for emergency use and it has seen huge success.

The company was founded in 1849 in New York by Charles Pfizer and Charles Erhart. At first, the company was a manufacturer of fine chemicals but pivoted to more research-based pharmaceuticals in the 1950s. Over the years, the company has had countless success stories, including Lipitor – touted as the biggest selling drug of all time. Another famous success story for the company is Viagra; while the drug was undergoing clinical trials for treating heart disease, scientists realized that it was not sufficiently efficacious – but also noted that it did have an unusual side effect…

As of February 2022, the company had 27 product candidates in phase I, 25 in phase II, and 27 in phase III.

Key facts

Global headquarters: New York, USA

Number of employees: 79,000

Sales Revenue in 2021: US$81.3 billion

Recent news:

Pfizer acquires ReViral and its portfolio of respiratory syncytial virus therapeutic candidates

David M Denton named company’s Chief Financial Officer

Pfizer-BioNTech COVID-19 vaccine receives expanded EUA from FDA for an additional booster in people aged 50 years and older

All profits from Pfizer’s Russia subsidiary will be donated to causes that provide direct humanitarian support to Ukraine

Honorable mention: Merck, Sharp & Dohme

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine